natgillin/translations-raw huggingface dataset:
Wind (flatulence), with or without oily spotting
Vjetrovi (nadutost), koji mogu biti praćeni izlučivanjem masti
Wind (flatulence), with or without oily spotting.
Vjetrovi (nadutost), koji mogu biti praćeni izlučivanjem masti
window (See Figure N).
stanja injekcije (vidjeti Sliku N).
window counter pointer selector button
doze doziranje
Wingates Industrial Estate Westhoughton, Bolton Lancashire BL5 3XX United Kingdom
Wingates Industrial Estate Westhoughton, Bolton Lancashire BL5 3XX Ujedinjena Kraljevina
Wingates Industrial Park Westhoughton, Bolton Lancashire BL5 3XX United Kingdom
Wingates Industrial Park Westhoughton, Bolton Lancashire BL5 3XX Ujedinjeno Kraljevstvo
Wingates Industrial Park Westhoughton, Bolton Lancashire, BL5 3XX United Kingdom
Wingates Industrial Park Westhoughton, Bolton Lancashire BL5 3XX Ujedinjeno Kraljevstvo
Wipe each vial top with a fresh alcohol pad.
Prebrišite vrh svake bočice novom vatom natopljenom alkoholom.
Wipe off the venous port of the hemodialysis as instructed by your healthcare provider
Obrišite otvor za injekciju na venskoj liniji za hemodijalizu sukladno uputama zdravstvenog djelatnika.
Wipe the area that you will inject with the alcohol swab provided.
Obrišite područje gdje ćete ubrizgati lijek priloženim alkoholnim tupferom.
Wipe the chosen area with an alcohol swab.
Obrišite odabrano mjesto blazinicom natopljenom
Wipe the injection site on the skin with an antiseptic wipe
Obrišite mjesto za davanje injekcije na koži antiseptičkom maramicom.
Wipe the injection site with a new alcohol swab.
Očistite mjesto za injiciranje novim tupferom s alkoholom.
Wipe the injection site with an alcohol swab.
Obrišite mjesto injekcije tupferom natopljenim alkoholom.
Wipe the injection site with the alcohol pad, if necessary.
Po potrebi obrišite mjesto injekcije vatom natopljenom alkoholom.
Wipe the injection site with the enclosed alcohol pad, using a circular motion.
Mjesto na kojem ćete ubrizgati injekciju kružnim pokretima prebrišite jastučićem natopljenim alkoholom.
Wipe the nozzle and inside of the cap with a clean, dry tissue – see pictures i and j.
Obrišite raspršivač i unutrašnjost zatvarača sa čistim, suhim rupčićem – pogledajte slike i i j.
Wipe the outside of the FORSTEO with a damp cloth.
Obrišite FORSTEO izvana vlažnom krpicom.
Wipe the outside of the syringe with a clean tissue.
Obrišite vanjski dio štrcaljke čistom maramicom.
Wipe the outside of the syringe with a clean tissue.
Čistom maramicom obrišite vanjsku stranu štrcaljke.
Wipe the rubber seal of the NutropinAq with rubbing alcohol or an antiseptic solution to prevent contamination of the contents by microorganisms that may be introduced by repeated needle insertions.
Obrišite gumeni zaštitni zatvarač lijeka NutropinAq alkoholom ili otopinom antiseptika kako bi spriječila kontaminacija sadržaja mikroorganizmima koji se mogu unijeti opetovanim umetanjima igle.
Wipe the rubber seal with a swab.
Gumeni zaštitni zatvarač obrišite tupferom.
Wipe the Rubber Seal with an alcohol swab.
Gumeni zaštitni zatvarač obrišite tupferom natopljenim alkoholom
Wipe the Rubber Seal with an alcohol swab.
Gumeni zaštitni zatvarač obrišite tupferom natopljenim alkoholom.
Wipe the rubber stopper and metal ring with your first alcohol swab.
Obrišite gumeni čep i metalni prsten s prvom alkoholom natopljenom blazinicom.
Wipe the site where Enbrel is to be injected with a new alcohol swab, using a circular motion.
Obrišite mjesto uboda gdje će se ubrizgati Enbrel novim jastučićem vate natopljene alkoholom, kružnim pokretom.
Wipe the site where Enbrel is to be injected with an alcohol swab, using a circular motion.
Obrišite mjesto uboda gdje će se ubrizgati Enbrel jastučićem vate natopljene alkoholom, kružnim pokretom.
Wipe the site where Nplate is to be injected with an alcohol swab, using a circular motion.
Kružnim pokretima obrišite mjesto na koje ćete ubrizgati Nplate, vaticom natopljenom alkoholom.
Wipe the top of the pre-filled pen where the needle is going to be attached with an alcohol swab (see Figure 4).
Vrh napunjene brizgalice na koji će se pričvrstiti igla obrišite tupferom s alkoholom (vidjeti Sliku 4).
Wipe the top of the vial of the reconstituted suspension with a sterile alcohol swab.
Obrišite vršak bočice s rekonstituiranom suspenzijom sterilnom vaticom natopljenom alkoholom.
Wipe the top of the vial with an alcohol swab.
Obrišite vrh bočice kompresom natopljenom alkoholom.
Wipe the vial’s rubber stopper with an alcohol swab and place it on your flat work surface.
Jastučićem natopljenim alkoholom obrišite gumeni čep na bočici i postavite ju na ravnu radnu plohu.
Wipe your injection site with an alcohol swab in a circular motion.
Kružnim pokretom obrišite mjesto injekcije vatom natopljenom alkoholom.
Wipe your skin by using the enclosed alcohol pad, using a circular motion.
Mjesto na kojem ćete ubrizgati injekciju kružnim pokretima prebrišite jastučićem natopljenim alkoholom.
Wipe your skin with an alcohol swab, and let the injection site dry before you inject your dose.
Obrišite kožu tupferom natopljenim alkoholom i pričekajte da se koža osuši prije primjene doze.
Wipe your skin with an alcohol swab, and let your skin dry before you inject your dose.
Obrišite kožu tupferom natopljenim alkoholom i pričekajte da se koža osuši prije primjene doze.
wirl the product vial with the transparent adapter attached until the substance is fully dissolved.
Polako okrećite bočicu s lijekom i prozirnim adapterom dok se sadržaj potpuno ne rastopi.
with
imptomi
with
ketokonazol
with 3 pen needles
pakiranja s 3 igle
with 3 pen needles
pakiranje s 3 igle
With a calculated adverse experience rate (per number of administrations) of 0,005% the frequency of these ADRs can be classified as very rare.
Uz izračunatu stopu nuspojava (po broju primjena) od 0,005 % učestalost ovih nuspojava može se svrstati u vrlo rijetke.
With a cleansing swab, disinfect both the rubber membrane of the vial with powder and the rubber membrane of the cartridge with solvent.
Tupferom za čišćenje, dezinficirajte gumene membrane na bočici s praškom i na ulošku s otapalom.
With a cleansing swab, disinfect the rubber membrane of the cartridge.
Tupferom za čišćenje, dezinficirajte gumenu membranu uloška.
with a clinically
klinički značajnim
With a continuous flow neonatal ventilator, this may be achieved by infusing a low flow of INOmax into the inspiratory limb of the ventilator circuit.
Pri upotrebi neonatalnog respiratora s kontinuiranim protokom, to se postiže ubrizgavanjem INOmax-a s niskim protokom u inspiratorni krak sustava respiratora.
with a history suggestive of torsades de pointes ventricular tachycardia (abnormal heart rhythms);
poviješću bolesti koja ukazuje na ventrikularnu tahikardiju torsades de pointes (abnormalni srčani ritmovi);
With a loading dose of 300 mg or 600 mg clopidogrel, dabigatran AUCτ,ss and Cmax,ss were increased by about 30-40 % (see section 4.4) (see also subsection on ASA below).
S udarnom dozom od 300 mg ili 600 mg klopidogrela, AUCτ,ss i Cmax,ss dabigatrana bili su povišeni za oko 30 - 40 % (vidjeti dio 4.4) (također vidi odlomak o ASA-i u nastavku teksta).
With a loading dose of 300 mg or 600 mg clopidogrel, dabigatran AUCτ,ss and Cmax,ss were increased by about 30-40 % (see section 4.4) (see also subsection on ASA below).
S udarnom dozom od 300 mg ili 600 mg klopidogrela, AUCτ,ss i Cmax,ss dabigatrana bili su povišeni za oko 30 - 40 % (vidjeti dio 4.4) (vidjeti također podnaslov o ASA-i u nastavku).
With a loading dose of 300 mg or 600 mg clopidogrel, dabigatran AUCτ,ss and Cmax,ss were increased by about 30-40 % (see section 4.4).
S udarnom dozom od 300 mg ili 600 mg klopidogrela, AUCτ,ss i Cmax,ss dabigatrana bili su povišeni za oko 30 - 40 % (vidjeti dio 4.4).
with a long history of diabetes,
koji već dugo boluju od dijabetesa
with a long history of diabetes,
koji već dugo boluju od dijabetesa,
with a long history of diabetes,
koji već dugo boluju od šećerne bolesti
with a long history of diabetes,
koji već dugo boluju od šećerne bolesti,
with a low dose ritonavir, it should
ritonavira indicirana sa sildenafilom,
with a low dose ritonavir, it should
ritonavira, primjena bi morala biti u
With a median duration of follow-up of 40 months, median OS (56.3 months in the R-CHOP group, and not reached in the BR-CAP group) favoured the BR-CAP group, (estimated HR=0.80; p=0.173).
S medijanom trajanja praćenja od 40 mjeseci, medijan OS (56,3 mjeseci u R-CHOP skupini, i nije postignut u BR-CAP skupini) bio je u korist BR-CAP skupine, (procijenjeni HR=0,80; p=0,173).
With a median duration of follow-up of 40 months, median OS (56.3 months in the R-CHOP group, and not reached in the BzR-CAP group) favoured the BzR-CAP group, (estimated HR=0.80; p=0.173).
S medijanom trajanja praćenja od 40 mjeseci, medijan OS (56,3 mjeseci u R-CHOP skupini, i nije postignut u BzR- CAP skupini) bio je u korist BzR-CAP skupine, (procijenjeni HR=0,80; p=0,173).
With a median duration of follow-up of 40 months, median OS (56.3 months in the R-CHOP group, and not reached in the VcR-CAP group) favoured the VcR-CAP group, (estimated HR=0.80; p=0.173).
S medijanom trajanja praćenja od 40 mjeseci, medijan OS (56,3 mjeseci u R-CHOP skupini, i nije postignut u
With a median observation time of 24.1 months for follicular lymphoma patients, 48 patients (28.1%) in the B arm and 30 patients (18.3%) in the G+B arm had died.
Tijekom medijana vremena promatranja bolesnika s folikularnim limfomom od 24,1 mjeseca preminulo je 48 bolesnika (28,1%) u skupini koja je primala bendamustin (B) i 30 bolesnika (18,3%) u skupini koja je primala obinutuzumab + bendamustin (G+B).
With a minimum of 60 months follow-up, 60% of patients randomised to the SPRYCEL group and 63% of patients randomised to the imatinib group were still receiving first-line treatment.
S najmanje 60 mjeseci praćenja bolesnika, 60% bolesnika randomiziranih u SPRYCEL skupinu i 63% bolesnika randomiziranih u imatinib skupinu primalo je terapiju za prvu liniju.
with a propensity to bleed (e.g. due to recent trauma, recent surgery, recent or recurrent gastrointestinal bleeding, or active peptic ulcer disease) with body weight < 60 kg (see sections 4.2 and 4.8).
koji su skloni krvarenju (npr. zbog nedavne traume, nedavnog kirurškog zahvata, nedavnog ili opetovanog gastrointestinalnog krvarenja ili aktivnog peptičnog ulkusa) tjelesne težine < 60 kg (vidjeti dijelove 4.2 i 4.8).
With a quick, short motion, push the needle all the way into the skin at an angle between 45° and 90° (see Diagram 10).
Brzim, kratkim pokretom ubodite iglu kroz kožu pod kutom između 45° i 90° (vidi sliku 10).
With a quick, short motion, push the needle all the way into the skin at an angle between 45° and 90° (see Diagram 13).
Brzim, kratkim pokretom ubodite iglu kroz kožu pod kutom između 45° i 90° (vidi sliku 13).
With a quick, short motion, push the needle all the way into the skin at an angle between 45° and 90° (see Diagram 18).
Brzim, kratkim pokretom ubodite iglu kroz kožu pod kutom između 45° i 90° (vidi sliku 18).
With a quick, short motion, push the needle all the way into the skin at an angle between 45° and 90° (see Diagram10).
Brzim, kratkim pokretom ubodite iglu kroz kožu pod kutom između 45° i 90° (vidi sliku 10).
With a short, sharp motion, push the needle into the skin.
Kratkim, žustrim pokretom, ubodite iglu u kožu.
With a significantly higher conversion rate in patients treated with BRINAVESS, the incidence of bradycardia events was higher within the first 2 hours in vernakalant treated patients than in placebo-treated patients (5.4% versus 3.8%, respectively).
Uz značajno veću stopu konverzije u bolesnika koji su primali BRINAVESS, incidencija bradikardije u prva 2 sata bila je veća u bolesnika liječenih vernakalantom nego u onih koji su primali placebo (5,4% naspram 3,8%).
With a slow elimination rate (mean half life = 14 h, mean total body clearance, CL/F, = 84 ml/h/kg), renal clearance is negligible (5% of total body clearance), assuming 100% bioavailability.
Sa sporom stopom eliminacije (srednji poluvijek = 14 h, srednja vrijednost ukupnog tjelesnog klirensa, CL/F, = 84 ml/h/kg), klirens putem bubrega je zanemariv (5% od ukupnog tjelesnog klirensa), podrazumijevajući 100%-tnu bioraspoloživost.
With a systemic clearance of about 10 l/h, rivaroxaban can be classified as a low-clearance substance.
Budući da mu sistemni klirens iznosi oko 10 l/h, rivaroksaban se može svrstati među lijekove s niskim klirensom.
with abacavir.
abakavirom.
With any baseline NS5A RAVs
S bilo kojim početnim NS5A RAV-ovima
with Aptivus, co-administered with
Aptivusom uz nisku dozu
with Aptivus, co-administered with
estrogena primjenjuju istodobno s
with Aptivus, co-administered with
Istodobna primjena se ne preporuča.
with Aptivus, co-administered with
primjenjuju istodobno s Aptivusom
with atazanavir/ritonavir is not
atazanavir (pm):
with atazanavir/ritonavir is not
primjena efavirenza s
with atorvastatin, fluvastatin,
s atorvastatinom, fluvastatinom,
with baseline and post- baseline sequence
a sekvencama na početku i nakon početka liječenja
With baseline CD4+ cell
S početnim brojem CD4+ stanica < 200
With Bazett’s correction (QTcB interval), the upper bound of one-sided 95% confidence interval (CI) for predicted effect on QTcB at Cmax was 5.9 msec.
Uz Bazettovu korekciju (QTcB interval), gornja granica jednostranog intervala pouzdanosti od 95% za predviđeni učinak na QTcB na Cmax bila je 5,9 msec.
with boosted PREZISTA it may cause a
PREZISTOM to može izazvati velik
with boosted PREZISTA.
pojačanom PREZISTOM.
with buprenorphine/naloxone.
buprenorfinom/naloksonom.
With Caelyx, the encapsulation of doxorubicin hydrochloride in pegylated liposomes results in these effects having a differing strength, as follows.
Kod Caelyxa, inkapsuliranost doksorubicinklorida u pegiliranim liposomima razultirarazličitom jačinom ovih učinaka, kako je dalje navedeno.
With cardiac disease
a srčanom bolešću
With careful rechallenge Fabrazyme has been re-administered to all 6 patients who tested positive for IgE antibodies or had a positive skin test to Fabrazyme in a clinical trial.
Uz oprez prilikom ponovnog uvođenja, Fabrazyme je ponovno primijenjen u svih 6 bolesnika koji su u kliničkom ispitivanju imali pozitivan nalaz na IgE protutijela i pozitivan rezultat kožnog testa na Fabrazyme.
with caution and a lower
primjenjivati s oprezom te se
with caution at reduced doses of no
primjenjivati uz oprez u sniženoj
with caution due to possible cardiac
oprez zbog mogućih srčanih
with caution.
mora primjenjivati s oprezom.
with CF who have a specified CFTR gating mutation and are aged 2 through 5
cističnom fibrozom, koja imaju utvrđenu mutaciju gena CFTR zbog koje dolazi
with chest pain due to heart disease (acute coronary syndromes - ACS) who are having surgery to treat blockages in their blood vessels (angioplasty and/or percutaneous coronary intervention - PCI).
koji imaju bolove u prsima zbog srčanih bolesti (akutni koronarni sindrom) koji imaju operaciju zbog blokade u krvnim žilama (angioplastiku i/ili perkutanu koronarnu intervenciju - PCI).
With cholestatic hepatitis
kolestatskim hepatitisom
with chronic lymphocytic leukaemia (a cancer of a type of white blood cell) and frequent bacterial infections after preventive treatment with antibiotics has failed;
kroničnom limfocitnom leukemijom (raka tipa bijelih krvnih stanica) i čestim bakterijskim infekcijama nakon što profilaksa antibioticima nije bila uspješna;
With chronic use in the RE-LY study, NSAIDs increased the risk of bleeding by approximately 50 % on both dabigatran etexilate and warfarin.
Kronična primjena NSAIL-a u RE-LY studiji povećala je rizik od krvarenja za oko 50 % i za dabigatran i varfarin.
With chronic use in the RE-LY study, NSAIDs increased the risk of bleeding by approximately 50% on both dabigatran etexilate and warfarin.
Kronična primjena NSAIL-a u RE-LY studiji povećala je rizik od krvarenja za oko 50 % i za dabigatran i varfarin.
With chronic use NSAIDs increased the risk of bleeding by approximately 50 % on both dabigatran etexilate and warfarin.
Kronična primjena NSAIL-a u RE-LY studiji povećala je rizik od krvarenja za oko 50 % i za dabigatran i varfarin.
with cirrhosis
s cirozom
With cirrhosis**
S cirozom
with cirrhosis, who are co-infected with HIV
s cirozom, koji su koinficirani HIV-om
With concomitant use of MTX, treatment with 50 mg golimumab subcutaneously every 4 weeks resulted in a mean ( standard deviation) steady-state trough serum concentration of approximately 0.6  0.4 g/mL in RA patients with active RA despite MTX therapy, and approximately 0.5  0.4 g/mL in patients with active PsA and approximately 0.8  0.4 g/mL in patients with AS.
Uz istodobnu primjenu metotreksata, liječenje golimumabom primijenjenim supkutano u dozi od 50 mg svaka 4 tjedna dovelo je do prosječne (± standardna devijacija) koncentracije u stanju dinamičke ravnoteže od približno 0,6 ± 0,4 g/ml u bolesnika s reumatoidnim artritisom aktivnim unatoč liječenju metotreksatom, približno 0,5 ± 0,4 g/ml u bolesnika s aktivnim psorijatičnim artritisom i približno 0,8 ± 0,4 g/ml u bolesnika s ankilozantnim spondilitisom.
With concomitant use with the CYP3A4 inhibitor erythromycin in young patients and diltiazem in elderly patients respectively, the plasma concentration of amlodipine increased by 22 % and 50 % respectively.
Uz istovremenu primjenu s CYP3A4 inhibitorom, eritromicinom kod mladih osoba te diltiazema kod starijih osoba, koncentracije amlodipina u plazmi povećale su se za 22% i 50%, po istom redoslijedu.
With concomitant use with the CYP3A4 inhibitor erythromycin in young patients and diltiazem in elderly patients respectively, the plasma concentration of amlodipine increased by 22 % and 50 % respectively.
Uz istovremenu primjenu s CYP3A4 inhibitorom, eritromicinom, kod mladih osoba te diltiazema kod starijih osoba, koncentracije amlodipina u plazmi povećale su se za 22 %, odnosno 50 %.
With continued application of Panretin redness and irritation may increase and swelling at the site of the application may develop.
S nastavkom primjene Panretina crvenilo i nadraženost mogu se pojačati i može nastati otok na mjestu primjene.
With continued daily dosing, the lymphocyte count continues to decrease over a two-week period, reaching a minimal count of approximately
Uz nastavak svakodnevnog doziranja, broj limfocita nastavlja se smanjivati tijekom razdoblja od dva tjedna te se postiže minimalni broj od približno
With continued long- term treatment, 11.4 % of the patients were seizure-free for at least 6 months and 7.2 % were seizure- free for at least 1 year.
S nastavkom dugotrajnog liječenja 11,4% bolesnika bilo je barem 6 mjeseci, a 7,2% barem 1 godinu bez napadaja.
With continued long- term treatment, 11.4 % of the patients were seizure-free for at least 6 months and 7.2 % were seizure- free for at least 1 year.
S nastavkom dugotrajnog liječenja 11,4% bolesnika bilo je barem 6 mjeseci, a 7,2% barem 1. godinu bez napadaja.
With continued long-term treatment, 28.6 % of the patients were free of myoclonic seizures for at least 6 months and 21.0 % were free of myoclonic seizures for at least 1 year.
S nastavkom dugotrajnog liječenja, 28,6% bolesnika bilo je barem 6 mjeseci i 21,0% barem 1 godinu bez miokloničkih napadaja.
With continued long-term treatment, 28.6% of the patients were free of myoclonic seizures for at least 6 months and 21.0 % were free of myoclonic seizures for at least 1 year.
S nastavkom dugotrajnog liječenja 28,6% bolesnika bilo je barem 6 mjeseci i 21,0% barem 1 godinu bez miokloničkih napadaja.
With continued long-term treatment, 8.6 % of the patients were seizure- free for at least 6 months and 7.8 % were seizure-free for at least 1 year.
Dugoročno je liječenje pokazalo da 8,6% bolesnika nije imalo napadaje tijekom najmanje 6 mjeseci, a njih 7,8% nije imalo napadaje tijekom najmanje 1 godine.
with continuous infusion (in
kontinuiranom infuzijom (u IU/kg/h)
With current data it is not known if infliximab treatment influences the risk for developing dysplasia or colon cancer (see section 4.8).
Na temelju trenutno dostupnih podataka nije poznato utječe li liječenje infliksimabom na rizik razvoja displazije ili karcinoma debelog crijeva (vidjeti dio 4.8).
With dabrafenib monotherapy, approximately 70% of events occurred within the first 12 weeks of treatment with a median time to onset of 8 weeks.
Uz monoterapiju dabrafenibom oko 70% događaja zabilježeno je unutar prvih 12 tjedana liječenja s medijanom vremena prvog javljanja od 8 tjedana.
with dasabuvir
dasabuvir
With delayed provisional eptifibatide administration, the event rates were 10% vs 11.5% in patients who received reduced dose and standard dose respectively (p=0.61).
Uz odgođenu privremenu primjenu eptifibatida, stope događaja su za bolesnike sa smanjenom dozom lijeka iznosile 10 % u odnosu na 11,5 % u bolesnika na standardnoj dozi (p=0,61).
With delayed provisional eptifibatide administration, the TIMI major events were 1.4% vs 2.0% in patients who received reduced dose and standard dose respectively (p=0.54).
Uz odgođenu privremenu primjenu eptifibatida, TIMI velika krvarenja su iznosila 1,4 % u bolesnika koji su primali smanjenu dozu naspram 2,0 % u bolesnika na standardnoj dozi (p=0,54).
with DFS and symptomatic
preživljenjem bez bolesti i
With double dose, a moderate palpable reaction of diameter of 4 to 5 cm was observed at the injection site, lasting for 4 days.
Uz dvostruku dozu, umjerena opipljiva reakcija promjera 4 do 5 cm zabilježena je na mjestu uboda, koji traje 4 dana.
With double dose, a moderate palpable reaction of diameter of 4 to 5 cm was observed at the injection site, lasting for 4 days.
Uz dvostruku dozu, umjerena opipljiva reakcija promjera 4 do 5 cm zabilježena je na mjestu uboda, koji traje četiri dana.
With dry hands press gently to release the tablet on your hand.
Suhim rukama nježno pritisnite kako biste tabletu oslobodili na dlan.
With dry hands, press gently to release the tablet on your hand.
Suhim rukama nježno pritisnite kako biste tabletu oslobodili na dlan.
With dry hands, remove capsule from the blister.
Suhim rukama izvadite kapsulu iz blistera.
With each new IONSYS application the patient may use IONSYS more frequently than during the remainder of the 24 hour dosing period, due to a lower absorption of fentanyl from the system for the first few hours (see section 5.2).
Pri svakoj primjeni novog sustava IONSYS, bolesnik može koristiti IONSYS češće nego tijekom preostalog razdoblja doziranja od 24 sata, zbog slabije apsorpcije fentanila iz sustava tijekom prvih nekoliko sati (vidjeti dio 5.2).
With each new pen, check the flow
Provjerite protok svaki puta kad uzmete novu brizgalicu
with efavirenz 600 mg daily.
efavirenzom 600 mg na dan.
With efavirenz, an increase of
farmakokinetika indinavira i efavirenza
with emergent NS5A RAVs***
s varijantama NS5A koje uzrokuju rezistenciju nastalima tijekom liječenja
with etravirine + PI, see below.
etravirinom + IP vidjeti dolje.
with etravirine.
s etravirinom.
With experience, you will find the angle that is most comfortable for the child.
S vremenom ćete naučiti odrediti kut koji djetetu najviše odgovara.
With experience, you will find the angle that is most comfortable for you or the child.
S vremenom ćete naučiti odrediti kut koji Vama ili djetetu najviše odgovara.
With experience, you will find the angle that is most comfortable for you.
S vremenom ćete naučiti odrediti kut koji Vam najviše odgovara.
with famotidine.
s famotidinom.
with fluconazole.
prvenstveno
with food).
primjenjuje s hranom).
With Grade 3 or 4 left ventricular cardiac dysfunction or if LVEF does not recover trametinib should be permanently discontinued (see section 4.4).
Ako bolesnik ima disfunkciju lijeve srčane klijetke 3. ili 4. stupnja ili ako se LVEF ne oporavi, liječenje trametinibom treba trajno obustaviti (vidjeti dio 4.4).
With hepatitis B vaccination at birth
S cijepljenjem protiv hepatitisa B po rođenju